Analyst Reco. Verastem, Inc.

Equities

VSTM

US92337C2035

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-14 pm EDT			5-day change	1st Jan Change
13.16 ^USD	+9.48%		+15.24%	+61.67%

May. 09	Verastem, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Apr. 18	Verastem Names John Hayslip as Chief Medical Officer	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Truist Securities Cuts Price Target on Verastem to $34 From $39, Maintains Buy Rating	Nov. 15	MT
B. Riley Starts Verastem at Buy With $21 PT, Notes Likely Accelerated Approval of Avutometinib + defactinib for Low-Grade Serous Ovarian Cancer	23-09-27	MT
RBC Cuts Price Target on Verastem to $32 From $34, Keeps Outperform Rating, Speculative Risk Qualifier	23-08-09	MT
Truist Securities Lowers Price Target on Verastem to $39 From $60, Maintains Buy Rating	23-07-11	MT
RBC Trims Price Target on Verastem to $34 From $36, Maintains Outperform Rating, Speculative Risk Qualifier	23-07-03	MT
Mizuho Upgrades Verastem to Buy From Neutral, Adjusts Price Target to $36 From $24	23-06-15	MT
HC Wainwright Trims Price Target on Verastem to $2 From $3, Keeps Buy Rating	23-05-10	MT
Mizuho Initiates Verastem at Neutral With $2 Price Target	23-03-30	MT
Verastem Says Ovarian Cancer Drug Combination Shows Objective Response Rate of 28% in Phase 2 Study	23-01-25	MT
HC Wainwright Adjusts Verastem's Price Target to $3 From $5, Keeps Buy Rating	22-11-07	MT
RBC Trims Verastem's Price Target to $3 From $5, Keeps Outperform, Speculative Risk Rating	22-11-04	MT
BTIG Adjusts Verastem's Price Target to $5 From $8, Maintains Buy Rating	22-10-05	MT
Alliance Global Reinstates Verastem at Buy, $6 Price Target	22-09-07	MT
RBC Initiates Verastem at Outperform With Speculative Risk Qualifier, $5 Price Target Amid Bullish View on Oncology Opportunity	22-04-14	MT
Truist Securities Initiates Verastem at Buy with $6 Price Target	22-03-09	MT
Verastem Oncology Announces Updated Investigator-Sponsored Phase 1/2 FRAME Study Data of VS-6766 with Defactinib in Low-Grade Serous Ovarian Cancer Showing Encouraging Response Rates and Progression-Free Survival Presented at ESMO 2021	21-09-19	CI
VERASTEM : HC Wainwright Adjusts Verastem's Price Target to $5 from $4, Keeps Buy Rating	21-07-20	MT
VERASTEM : Alliance Global Starts Verastem at Buy With $6 Price Target	21-07-01	MT
VERASTEM : BTIG Research Upgrades Verastem to Buy From Neutral, $8 Price Target	21-05-24	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.

BENEFIT NOW